MX2018008639A - Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
MX2018008639A
MX2018008639A MX2018008639A MX2018008639A MX2018008639A MX 2018008639 A MX2018008639 A MX 2018008639A MX 2018008639 A MX2018008639 A MX 2018008639A MX 2018008639 A MX2018008639 A MX 2018008639A MX 2018008639 A MX2018008639 A MX 2018008639A
Authority
MX
Mexico
Prior art keywords
same
azaphosphinane
phosphinane
derivatives
novel
Prior art date
Application number
MX2018008639A
Other languages
English (en)
Other versions
MX367319B (es
Inventor
Rupin Alain
Sansilvestri-Morel Patricia
Vallez Marie-Odile
Gloanec Philippe
Mennecier Philippe
Pierre SCHAFFNER Arnaud-
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55752640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018008639(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2018008639A publication Critical patent/MX2018008639A/es
Publication of MX367319B publication Critical patent/MX367319B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula (I) (ver Fórmula) en la que: Ak1 representa una cadena alquilo, X representa -(CH2)m-,-CH (R)-,-N(R)-,-CH2-N(R)-,-N (R)-CH2-o-CH2-N(R)-CH2-,m y R son tales como se han definido en la descripción, R1 y R2 representan cada uno H cuando X representa -(CH2)m-,-CH (R)-,-N (R)-,-CH2-N(R)-o-N (R)-CH2-, o bien forman juntos una unión cuando X representa -CH2-N (R)-CH2-,R3 representa NH2, Cy-NH2, Cy-Ak3-NH2 o piperidin-4-ilo, Cy y Ak3 son tales como se han definido en la descripción, R4 y R5, idénticos o diferentes, representan cada uno H o F, sus isómeros ópticos, así como sus sales de adición a un ácido farmacéuticamente aceptable.Medicamentos.
MX2018008639A 2016-01-14 2017-01-13 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. MX367319B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1670004A FR3046793B1 (fr) 2016-01-14 2016-01-14 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2017/050075 WO2017121969A1 (fr) 2016-01-14 2017-01-13 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
MX2018008639A true MX2018008639A (es) 2018-11-19
MX367319B MX367319B (es) 2019-08-15

Family

ID=55752640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008639A MX367319B (es) 2016-01-14 2017-01-13 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.

Country Status (47)

Country Link
US (2) US10138260B2 (es)
EP (1) EP3271368B1 (es)
JP (1) JP2019504070A (es)
KR (1) KR20180101522A (es)
CN (1) CN108495857A (es)
AR (1) AR107433A1 (es)
AU (1) AU2017207003B2 (es)
BR (1) BR112018014020A2 (es)
CA (1) CA3011184C (es)
CL (1) CL2018001862A1 (es)
CO (1) CO2018007271A2 (es)
CU (1) CU20180072A7 (es)
CY (1) CY1121154T1 (es)
DK (1) DK3271368T3 (es)
DO (1) DOP2018000165A (es)
EA (1) EA035072B1 (es)
EC (1) ECSP18051972A (es)
ES (1) ES2709376T3 (es)
FR (1) FR3046793B1 (es)
GE (1) GEP20207092B (es)
HK (1) HK1244283B (es)
HR (1) HRP20190193T1 (es)
HU (1) HUE042924T2 (es)
IL (1) IL260425B (es)
JO (1) JO3660B1 (es)
LT (1) LT3271368T (es)
MA (1) MA41798B1 (es)
MD (1) MD3271368T2 (es)
ME (1) ME03305B (es)
MX (1) MX367319B (es)
NI (1) NI201800073A (es)
PE (1) PE20181503A1 (es)
PH (1) PH12018501373A1 (es)
PL (1) PL3271368T3 (es)
PT (1) PT3271368T (es)
RS (1) RS58338B1 (es)
RU (1) RU2729641C2 (es)
SG (1) SG11201805757WA (es)
SI (1) SI3271368T1 (es)
SV (1) SV2018005721A (es)
TN (1) TN2018000226A1 (es)
TR (1) TR201820430T4 (es)
TW (1) TWI625334B (es)
UA (1) UA121275C2 (es)
UY (1) UY37072A (es)
WO (1) WO2017121969A1 (es)
ZA (1) ZA201804391B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311488T1 (sl) * 2000-08-17 2010-01-29 Pfizer Ltd Substituirani imidazoli kot inhibitorji TAFIA
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
WO2003076416A1 (en) * 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
WO2005058330A1 (en) * 2003-12-17 2005-06-30 Quatrx Pharmaceuticals Co. Phosphorus containing compounds useful for the regulation of ldl and lp(a) levels
WO2006113247A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
AU2008266883B2 (en) * 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102498118A (zh) * 2009-09-09 2012-06-13 吉里德科学公司 黄病毒科病毒的抑制剂
EP2875001B1 (en) * 2012-07-18 2019-01-09 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PH12018501373B1 (en) 2019-02-27
SG11201805757WA (en) 2018-08-30
GEP20207092B (en) 2020-04-10
IL260425B (en) 2020-05-31
US10138260B2 (en) 2018-11-27
AU2017207003A2 (en) 2018-10-04
WO2017121969A1 (fr) 2017-07-20
TW201726697A (zh) 2017-08-01
MA41798A (fr) 2018-01-24
PL3271368T3 (pl) 2019-04-30
JO3660B1 (ar) 2020-08-27
EA201891599A1 (ru) 2019-01-31
HK1244283B (zh) 2019-11-22
CY1121154T1 (el) 2020-05-29
US20190031693A1 (en) 2019-01-31
TN2018000226A1 (fr) 2019-10-04
CU20180072A7 (es) 2018-10-04
EA035072B1 (ru) 2020-04-23
ME03305B (me) 2019-10-20
TR201820430T4 (tr) 2019-01-21
UA121275C2 (uk) 2020-04-27
US20180016288A1 (en) 2018-01-18
PH12018501373A1 (en) 2019-02-27
CL2018001862A1 (es) 2018-10-05
NI201800073A (es) 2018-09-06
EP3271368A1 (fr) 2018-01-24
AR107433A1 (es) 2018-05-02
KR20180101522A (ko) 2018-09-12
SV2018005721A (es) 2018-09-06
HRP20190193T1 (hr) 2019-04-05
BR112018014020A2 (pt) 2018-12-11
RS58338B1 (sr) 2019-03-29
ES2709376T3 (es) 2019-04-16
AU2017207003B2 (en) 2020-10-08
CN108495857A (zh) 2018-09-04
CA3011184C (fr) 2020-09-29
PE20181503A1 (es) 2018-09-18
RU2729641C2 (ru) 2020-08-11
PT3271368T (pt) 2018-12-04
AU2017207003A1 (en) 2018-07-26
HUE042924T2 (hu) 2019-07-29
ECSP18051972A (es) 2018-07-31
FR3046793B1 (fr) 2018-01-05
CA3011184A1 (fr) 2017-07-20
EP3271368B1 (fr) 2018-10-31
ZA201804391B (en) 2020-01-29
MA41798B1 (fr) 2018-11-30
DK3271368T3 (da) 2019-02-25
TWI625334B (zh) 2018-06-01
MD3271368T2 (ro) 2019-03-31
RU2018129027A3 (es) 2020-03-19
SI3271368T1 (sl) 2019-02-28
CO2018007271A2 (es) 2018-07-19
RU2018129027A (ru) 2020-02-14
JP2019504070A (ja) 2019-02-14
FR3046793A1 (fr) 2017-07-21
MX367319B (es) 2019-08-15
UY37072A (es) 2017-07-31
US10654878B2 (en) 2020-05-19
LT3271368T (lt) 2018-12-10
DOP2018000165A (es) 2018-09-15

Similar Documents

Publication Publication Date Title
PH12018500425A1 (en) Novel 6-6 bicyclic aromatic ring substituted nuceloside analogues for use as prmt5 inhibitors
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
SA518392049B1 (ar) مشتقات أمونيوم جديدة، عملية لتحضيرها وتركيبات صيدلانية تحتوي عليها
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
TN2018000106A1 (en) Farnesoid x receptor modulators
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2017014035A (es) Formas solidas novedosas.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201990455A1 (ru) КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201890532A1 (ru) Новые аннелированные бензамиды
PH12019500822A1 (en) Crystalline forms of eravacycline
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
PH12018501373A1 (en) Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.

Legal Events

Date Code Title Description
FG Grant or registration